Paolo Macchiarini is one of a small group of people in the stem cell universe whose misconduct has blown up in the press. Piero Anversa, Haruko Obokata, Hwang Woo-Suk, and some operators in the unproven stem cell clinic sphere come to mind. Macchiarini published quite a few seriously problematic papers, some of which just hung […]
Weekly reads: late Macchiarini retractions, stem cells & Lululemon Read More »
A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial
Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »
So many things have gotten very expensive these days that it got me thinking this past week again about stem cell cost. For this reason, I’ve been running polls asking people what they’ve paid for stem cells and how many therapies they’ve gotten. Before jumping into our weekly reads, check out our informational post on
Weekly reads: stem cell cost, trial death, HSCT for MS, Neuralink Read More »
I often get asked about where things stand with stem cell therapy for back pain, which is the focus of today’s post. Back pain is a complex condition with many potential causes. New treatments are needed as existing approaches often don’t work that well. What about stem cells? Stem cell therapy or other cell therapy
Can stem cell therapy for back pain work? Read More »
Are there endogenous adult heart stem cells that are useful in cardiac disease or can stem cell infusions help ailing hearts? As to the first question, the adult heart does not appear to have meaningful numbers of true stem cells. Further, testing the idea of infusions of stem cells for heart disease has so far been giving
Heart stem cells trial mostly disappoints but is oversold Read More »
Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they
2023 stem cell & regenerative medicine predictions Read More »
How much promise is there today for stem cell therapy for heart disease? Where do things stand with the clinical research? Patients regularly ask me these kinds of questions. The goal of today’s post is to update you on where things stand. What’s in this post Stem Cell Therapy | Clinical Trials | Delivery of
Stem cell therapy for heart disease: what you need to know Read More »
I am in the unique position of being a stem cell scientist who has no commercial interest in selling therapies so I can be impartial on giving patients and consumers guidance. In today’s post I give an overview of stem cell therapy and provide an expert, unbiased guide to navigating this area. This post is
Updated patients guide to stem cell therapy for 2024 Read More »
A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
One of the most common questions I’ve gotten over the last decade is, “how much does stem cell therapy cost?” They actually seem most often to want to know more specifically how much it should cost. To try to authoritatively answer this now in 2023 we need data from the present and past along with expert
How much does stem cell therapy cost in 2023? Read More »